Thyroid Eye Disease: Management Across the Spectrum of Severity and Chronicity (CME Monograph)

Activity Description and Purpose

This educational activity provides clinicians who currently treat patients with thyroid eye disease (TED) or have an interest in managing patients with TED with expert advice on diagnosis, current treatment approaches, and comanagement across the multidisciplinary team. A focused discussion on comanagement among eye care professionals and an endocrinologist provides the learner with practical strategies to optimize patient care. The desired results of this activity are to increase appropriate treatment of chronic TED in practice and to foster competent interdisciplinary collaboration to ensure the best possible outcomes for patients with chronic TED.

Target Audience

This educational activity is intended for ophthalmologists.

Learning Objectives

After completing this activity, participants will be better able to:

  • Identify patients with thyroid eye disease who would be optimal candidates for treatment with biologic therapies
  • Apply evidence to manage thyroid eye disease in patients with chronic disease
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Course opens: 
Course expires: 


Wendy W. Lee, MD, MS (Chair)
Professor of Clinical Ophthalmology and Dermatology
Oculofacial Plastic & Reconstructive Surgery, Orbit, and Oncology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
Miami, Florida

Roger A. Dailey, MD
Professor Ophthalmology
Lester T. Jones Chair of Oculoplastic Surgery
Casey Eye Institute
Oregon Health & Science University
Portland, Oregon

Andrew R. Harrison, MD
Department of Ophthalmology and Visual Neurosciences
Department of Otolaryngology, Head and Neck Surgery
Director, Ophthalmic Plastic and Reconstructive Surgery Service
Co-Director, Center for Thyroid Eye Disease
University of Minnesota
Minneapolis, Minnesota

Sonalika Khachikian, MD
Monument Health Rapid City Clinic
Rapid City, South Dakota

Disclosure Policy

MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.


Roger A. Dailey, MD, is a consultant for Amgen Inc and Viridian Therapeutics, Inc.

Andrew R. Harrison, MD, is a consultant for Amgen Inc and RVL Pharmaceuticals, Inc; and is on the speakers bureau for Amgen Inc and RVL Pharmaceuticals, Inc.

Sonalika Khachikian, MD, is a consultant for Amgen Inc; is on the speakers bureau for Amgen Inc; and is on the advisory board of Novo Nordisk A/S*.

Wendy W. Lee, MD, MS, is a consultant for Allergan, Amgen Inc, Novabay Pharmaceuticals, Inc, Revance Therapeutics, Inc, RVL Pharmaceuticals, Inc, and Tarsus Pharmaceuticals, Inc; and is a contracted researcher for Viridian Therapeutics, Inc.

Peer Reviewer

Hadi Kaakour, MD, was formerly an advisory board member of Alimera Sciences*.

Planners, Managers, and Writers

Carrie Allen, PharmD, BCPP, BCPS, MedEdicus Content Manager for this activity, was previously employed by CVS within the past 2 years, but that relationship has ended.

Other MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.

Medical Writer: Tony Realini, MD, MPH,  is a consultant for New World Medical, Inc, Ocular Therapeutix, Inc, Oyster Point Pharma Inc, and Sight Sciences; and was previously a consultant for iStar Medical and Ivantis Inc within the past 2 years, but those relationships have ended.

* The financial relationship existed during the past 24 months but has now ended

Accreditation Statement

MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Commercial Support

This continuing medical education activity is supported through an educational grant from Amgen Inc.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at


The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Amgen Inc.

©2024 MedEdicus LLC. 304.2a

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Please login or register to take this course.

Clicking Register/Take course indicates that you have reviewed the CME information for this activity.